Drugs / PBCAR269A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04171843 | Apr 2020 → Oct 2022 | refractory plasma cell neoplasm | Precision BioSciences, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-12-11 | Precision BioSciences, Inc. | Results Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline precisionbiosciences.com ↗
Overall, PBCAR269A monotherapy response observed in the Phase 1/2a trial was not comparable with autologous CAR T profiles. |
| 2020-09-09 | Precision BioSciences, Inc. | Regulatory Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma precisionbiosciences.com ↗
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PBCAR269A for the treatment of relapsed/refractory multiple myeloma. |
| 2020-01-13 | Precision BioSciences, Inc. | Regulatory Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma precisionbiosciences.com ↗
The FDA has also granted Orphan Drug Designation to PBCAR269A for the treatment of multiple myeloma. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBCAR269A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04171843 ↗ |
| Modality | Cell therapy | “Allogeneic anti-BCMA CAR T-cell” NCT04171843 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion of PBCAR269A” NCT04171843 ↗ |